Hypertensive Mediated Organ Damage and Hypertension Management. How to Assess Beneficial Effects of Antihypertensive Treatments?

被引:27
作者
Piskorz, Daniel [1 ]
机构
[1] Rosario British Sanat Cardiol Inst, RA-2000 Rosario, Central Argenti, Argentina
关键词
Hypertensive mediated organ damage; Cardiovascular risk; Hypertension management; LEFT-VENTRICULAR MASS; CARDIOVASCULAR RISK; BLOOD-PRESSURE; SUBCLINICAL ATHEROSCLEROSIS; AORTIC STIFFNESS; VASCULAR EVENTS; HEART-FAILURE; REDUCTION; SPIRONOLACTONE; METAANALYSIS;
D O I
10.1007/s40292-020-00361-6
中图分类号
R6 [外科学];
学科分类号
1002 ; 100210 ;
摘要
The presence of hypertensive mediated organ damage is related to increased vascular risk and mortality and its prevention should be a therapeutic target and a surrogate marker of in/adequate blood pressure control. In old adult hypertensive patients the therapeutic target should be to prevent major cardiovascular events, but in young hypertensive subjects the focus should be pointed on preventing the development of hypertensive mediated organ damage, since most of the hard events are preceded by functional and structural tissues injury. Hypertension Guidelines of the European Society of Cardiology and European Society of Hypertension recognizes that some variables like electrocardiographic or echocardiographic left ventricle hypertrophy, chronic kidney disease or advance retinopathy, all considered as hypertensive mediated organ damage, may be modifiers of cardiovascular risk estimated by the SCORE system, and for that reason they should be screened in hypertensive patients. It is well known the problem of limited health systems financial resources in many low and even median income countries which precludes the possibilities of generalizing the search for hypertension mediated organ damage in all hypertensive patients. In these scenario the recommendation to perform a detailed screening should be critically evaluated. Some questions remained unanswered: the screening generalization of hypertensive mediated organ damage should modify the cardiovascular risk score of the patients, if its presence could modify the therapeutic approach, and as a consequence, if the treatment adjustment should prolong life expectancy and ameliorate the quality of life.
引用
收藏
页码:9 / 17
页数:9
相关论文
共 45 条
[41]   Microalbuminuria reduction with valsartan in patients with type 2 diabetes mellitus - A blood pressure-independent effect [J].
Viberti, G ;
Wheeldon, NM .
CIRCULATION, 2002, 106 (06) :672-678
[42]  
Williams B, 2018, J HYPERTENS, V36, P2284, DOI [10.1097/HJH.0000000000001961, 10.1097/HJH.0000000000002026]
[43]   Real role of β-blockers in regression of left ventricular mass in hypertension patients Bayesian network meta-analysis [J].
Xing, FuWei ;
Chen, Jialin ;
Zhao, BinLiang ;
Jiang, Jingzhou ;
Tang, Anli ;
Chen, Yili .
MEDICINE, 2017, 96 (10)
[44]  
Yancy CW, 2017, CIRCULATION, V136, pE137, DOI [10.1161/CIR.0000000000000509, 10.1016/j.cardfail.2017.04.014]
[45]   Blood-Pressure and Cholesterol Lowering in Persons without Cardiovascular Disease [J].
Yusuf, Salim ;
Lonn, Eva ;
Pais, Prem ;
Bosch, Jackie ;
Lopez-Jaramillo, Patricio ;
Zhu, Jun ;
Xavier, Denis ;
Avezum, Alvaro ;
Leiter, Lawrence A. ;
Piegas, Leopoldo S. ;
Parkhomenko, Alexander ;
Keltai, Matyas ;
Keltai, Katalin ;
Sliwa, Karen ;
Chazova, Irina ;
Peters, Ron J. G. ;
Held, Claes ;
Yusoff, Khalid ;
Lewis, Basil S. ;
Jansky, Petr ;
Khunti, Kamlesh ;
Toff, William D. ;
Reid, Christopher M. ;
Varigos, John ;
Accini, Jose L. ;
McKelvie, Robert ;
Pogue, Janice ;
Jung, Hyejung ;
Liu, Lisheng ;
Diaz, Rafael ;
Dans, Antonio ;
Dagenais, Gilles .
NEW ENGLAND JOURNAL OF MEDICINE, 2016, 374 (21) :2032-2043